AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03218930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: General practitioners will receive a package of educational sessions tailored towards their specific needs.
Study NCT03218930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational materials
Description: Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
Study NCT04583956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Risankizumab placebo will be given at an equal volume at the same schedule.
Study NCT04583956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study NCT04583956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study NCT04583956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
Study NCT04930263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
Study NCT04930263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: control group received routine care and a manual on healthy living
Study NCT03236727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
Study NCT01775878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring Device
Description: Telemonitoring device was installed in patients' homes
Study NCT03674476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study NCT03674476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BMS-986036
Description: Specified dose on specified days
Study NCT04379310 — intervention group
Intervention type: DRUG
Intervention: ACE Inhibitors and Calcium Channel Blockers
Description: effect of drugs on patients with covid-19 pneumonia
Study NCT03014024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
Study NCT03014024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser therapy
Description: This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
Study NCT00065845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burch urethropexy at time of sacrocolpopexy
Description: The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
Study NCT01143584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point.
Study NCT01143584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also >50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk.
Study NCT04602247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC
Description: Sodium Iron Chlorophyllin, whose bioavailability is to be studied
Study NCT04602247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC + AA combined
Description: Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
Study NCT02961283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN003 ascending doses
Study NCT02961283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN003 MTD
Description: The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
Study NCT04602247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: Ferrous sulfate serves as a positive control, whose iron bioavailability is known
Study NCT04602247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4 + AA combined
Description: Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
Study NCT04602247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EP + FeSO4 combined
Description: Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
Study NCT04602247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EP + FeSO4 + AA combined
Description: Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
Study NCT05564585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio tape was applied over the calf muscle of either leg.
Study NCT05564585 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: The sham tape was applied over the calf muscle of either leg.
Study NCT06224803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Compound plant extracts
Description: Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
Study NCT06224803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Indigestible dextrin
Description: Indigestible dextrin as placebo intervention
Study NCT03336164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling Nutri-Score
Description: Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
Study NCT04434703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin (PRF)
Description: following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
Study NCT04434703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced platelet rich fibrin (A-PRF)
Description: following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
Study NCT04434703 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: blood clot
Description: following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
Study NCT00503321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)
Description: S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
Study NCT00503321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur/gimeracil/oteracil potassium (S-1)
Description: S-1 80mg/m2, 4weeks on followed by 2 weks off
Study NCT00642447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: helium:oxygen mixture
Study NCT01093391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRUG ELUTING STENT
Description: Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
Study NCT01093391 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BARE METAL STENT
Description: Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
Study NCT01505439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study NCT02854748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days
Study NCT02854748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days
Study NCT02854748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
Study NCT03073122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI, neurocognitive and psychological testing
Description: MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
Study NCT04198376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A The Laterally Closed Tunnel Technique with SCTG
Description: Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
Study NCT04198376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B Modified Coronally Advanced Tunnel Technique with SCTG.
Description: In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
Study NCT00081900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DENSPM )
Description: Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
Study NCT03145584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Bupivacaine via Adductor Canal Saphenous Catheter
Description: 12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
Study NCT03145584 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Single Shot Adductor Canal Saphenous Block with Bupivacaine
Description: A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
Study NCT00735839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
Study NCT00735839 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo (0.5 ml) single injection on Day 1
Study NCT02665039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min
Study NCT02665039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
Study NCT02665039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
Study NCT02665039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
Study NCT00346398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral mucosal immunoprophylaxis (OMIP)
Description: OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
Study NCT00346398 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
Study NCT00848094 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 3DCRT/IMRT
Description: The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
Study NCT00848094 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 3DCRT/IMRT
Description: The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
Study NCT03008785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
Study NCT03008785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
Study NCT03008785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily supplementation in 1 capsule per day containing starch of corn.
Study NCT01709630 — intervention group
Intervention type: DRUG
Intervention: Magnesium sulfate infusion
Description: Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
Study NCT05125549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Study NCT05125549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Study NCT00709787 — intervention group
Intervention type: OTHER
Intervention: Usual Care
Description: Normal care for hypertensive patients with risk factors for CHD
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004-IMP1
Description: daily topical application
Study NCT04581551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWE assessor 1
Description: SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor
Study NCT04581551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWE assessor 1
Description: SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor
Study NCT04581551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWE assessor 2
Description: SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor
Study NCT04581551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretch intervention
Description: Transversal stretch of pectoralis major muscle on the hemiplegic side.
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004-IMP1
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004-IMP1
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP2
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP2
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP2
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP3
Description: daily topical application
Study NCT04581551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No stretch intervention
Description: Passive mobilisation of the hemiplegic hand.
Study NCT00235716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopherol
Description: Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E.
Study NCT01829542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried blueberry powder dissolved in water
Description: Wild blueberry freeze-dried powder dissolved in water
Study NCT01829542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Macro- and micro-nutrient matched control in water